Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
News|Articles|April 11, 2026
FDA tracker: Novel approvals in pediatrics during 2026
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Kelly King
A review of 6 novel drugs approved by the FDA, with links to coverage from Contemporary Pediatrics and other MJH Life Sciences brands.
Advertisement
Advertisement
Multiple strides in pediatric care have been reported so far in 2026, marking a transformative year for the treatment of rare pediatric disorders and chronic dermatologic conditions. From the first targeted therapy for neurologic complications in Hunter syndrome and novel interventions for ultrarare diseases such as Menkes disease and arginase 1 deficiency, to historic firsts in oral and topical treatments for plaque psoriasis and atopic dermatitis in children and adolescents, clinical innovation is rapidly expanding the therapeutic tool kit available to pediatricians.
Related to this article
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Advertisement
Advertisement